Pharnext announced data and analysis from the phase 3 PLEO-CMT trial evaluating PXT3003 in Charcot-Marie-Tooth disease Type 1A (CMT1’), have been published in the Orphanet Journal of Rare…
Biogen announced complete results from the phase 3 VALOR study of tofersen (BIIB067), an antisense drug under development for patients with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis…
Denali Therapeutics announced positive clinical results and regulatory progress for two investigational small molecule therapeutics in development for the treatment of amyotrophic lateral sclerosis (ALS).…
Brainstorm Cell Therapeutics reported results from a multicenter, open-label phase 2 trial of NurOwn in progressive multiple sclerosis. Results showed a good safety and tolerability profile,…
Sanofi presented data from a Phase 2b long-term extension study (LTS) evaluating tolebrutinib in patients with relapsing forms of multiple sclerosis (RMS). The results showed that after 48…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
